A long story made too short: surrogate variables and the communication of HPV vaccine trial results

Gerhardus A, Razum O (2010)
JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH 64(5): 377-378.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
DOI
Autor*in
Gerhardus, Ansgar; Razum, OliverUniBi
Einrichtung
Fakultät für Gesundheitswissenschaften > AG 3 Epidemiologie & International Public Health
Erscheinungsjahr
2010
Zeitschriftentitel
JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH
Band
64
Ausgabe
5
Seite(n)
377-378
ISSN
0143-005X
Page URI
https://pub.uni-bielefeld.de/record/1795958

Zitieren

Gerhardus A, Razum O. A long story made too short: surrogate variables and the communication of HPV vaccine trial results. JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH. 2010;64(5):377-378.
Gerhardus, A., & Razum, O. (2010). A long story made too short: surrogate variables and the communication of HPV vaccine trial results. JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 64(5), 377-378. https://doi.org/10.1136/jech.2009.090183
Gerhardus, Ansgar, and Razum, Oliver. 2010. “A long story made too short: surrogate variables and the communication of HPV vaccine trial results”. JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH 64 (5): 377-378.
Gerhardus, A., and Razum, O. (2010). A long story made too short: surrogate variables and the communication of HPV vaccine trial results. JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH 64, 377-378.
Gerhardus, A., & Razum, O., 2010. A long story made too short: surrogate variables and the communication of HPV vaccine trial results. JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 64(5), p 377-378.
A. Gerhardus and O. Razum, “A long story made too short: surrogate variables and the communication of HPV vaccine trial results”, JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, vol. 64, 2010, pp. 377-378.
Gerhardus, A., Razum, O.: A long story made too short: surrogate variables and the communication of HPV vaccine trial results. JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH. 64, 377-378 (2010).
Gerhardus, Ansgar, and Razum, Oliver. “A long story made too short: surrogate variables and the communication of HPV vaccine trial results”. JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH 64.5 (2010): 377-378.

13 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

Listen to the public and fulfil their information interests - translating vaccine communication research findings into guidance for regulators.
Bahri P, Castillon Melero M., Br J Clin Pharmacol 84(8), 2018
PMID: 29573274
Application of real-time global media monitoring and 'derived questions' for enhancing communication by regulatory bodies: the case of human papillomavirus vaccines.
Bahri P, Fogd J, Morales D, Kurz X, ADVANCE consortium., BMC Med 15(1), 2017
PMID: 28464900
An Ethical Justification for Expanding the Notion of Effectiveness in Vaccine Post-Market Monitoring: Insights from the HPV Vaccine in Canada.
Komparic A, Smith MJ, Thompson A., Public Health Ethics 9(1), 2016
PMID: 26955399
A cost-utility analysis of cervical cancer screening and human papillomavirus vaccination in the Philippines.
Guerrero AM, Genuino AJ, Santillan M, Praditsitthikorn N, Chantarastapornchit V, Teerawattananon Y, Alejandria M, Toral JA., BMC Public Health 15(), 2015
PMID: 26223975
On the relationship between human papilloma virus vaccine and autoimmune diseases.
Pellegrino P, Carnovale C, Pozzi M, Antoniazzi S, Perrone V, Salvati D, Gentili M, Brusadelli T, Clementi E, Radice S., Autoimmun Rev 13(7), 2014
PMID: 24468416
Ethical considerations in post-market-approval monitoring and regulation of vaccines.
Thompson A, Komparic A, Smith MJ., Vaccine 32(52), 2014
PMID: 25454882
HPV vaccines and cancer prevention, science versus activism.
Tomljenovic L, Wilyman J, Vanamee E, Bark T, Shaw CA., Infect Agent Cancer 8(1), 2013
PMID: 23369430
Human papilloma virus vaccine and primary ovarian failure: another facet of the autoimmune/inflammatory syndrome induced by adjuvants.
Colafrancesco S, Perricone C, Tomljenovic L, Shoenfeld Y., Am J Reprod Immunol 70(4), 2013
PMID: 23902317
Too fast or not too fast: the FDA's approval of Merck's HPV vaccine Gardasil.
Tomljenovic L, Shaw CA., J Law Med Ethics 40(3), 2012
PMID: 23061593
No autoimmune safety signal after vaccination with quadrivalent HPV vaccine Gardasil?
Tomljenovic L, Shaw CA., J Intern Med 272(5), 2012
PMID: 22540172
Who profits from uncritical acceptance of biased estimates of vaccine efficacy and safety?
Tomljenovic L, Shaw CA., Am J Public Health 102(9), 2012
PMID: 22813421
Human papillomavirus vaccination in Africa.
Ouedraogo N, Müller O, Jahn A, Gerhardus A., Lancet 378(9788), 2011
PMID: 21784261
[Do media reports and public brochures facilitate informed decision making about cervical cancer prevention?].
Neumeyer-Gromen A, Bodemer N, Müller SM, Gigerenzer G., Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 54(11), 2011
PMID: 22015792
Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®
Quellen

PMID: 20445208
PubMed | Europe PMC

Suchen in

Google Scholar